Bruce W Bode Selected Research

Bruce W Bode Research Topics

Disease

41	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 01/2002
39	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 05/2005
17	Type 2 Diabetes Mellitus (MODY) 12/2020 - 09/2003
12	Hyperglycemia 01/2022 - 10/2005
8	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022 - 07/2013
7	Body Weight (Weight, Body) 01/2021 - 07/2011
5	Weight Gain 10/2018 - 01/2002
4	Weight Loss (Weight Reduction) 12/2020 - 07/2015
4	Critical Illness (Critically Ill) 01/2017 - 03/2004
2	Infections 09/2018 - 01/2016
2	Diabetes Mellitus 01/2007 - 11/2002
1	Diarrhea 09/2018
1	Nausea 02/2017
1	Obesity 02/2016
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2016
1	Cough 12/2015
1	Insulin Resistance 01/2013
1	Body Weight Changes 12/2011
1	Ketosis 06/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 09/2009
1	Pain (Aches) 01/2007
1	Inflammation (Inflammations) 01/2007
1	Myocardial Infarction 03/2004

Drug/Important Bio-Agent (IBA)

49	Insulin (Novolin)FDA Link 01/2022 - 05/2002
35	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2005
11	Blood Glucose (Blood Sugar)IBA 01/2022 - 03/2004
11	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 08/2005
11	Insulin Aspart (NovoLog)FDA Link 01/2019 - 09/2003
6	Hemoglobins (Hemoglobin)IBA 01/2020 - 08/2010
5	Insulin Lispro (Humalog)FDA Link 01/2022 - 05/2005
5	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 06/2019 - 09/2009
4	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 01/2021 - 07/2015
4	insulin degludecIBA 01/2019 - 08/2014
3	Sodium-Glucose Transport ProteinsIBA 06/2019 - 07/2015
3	Sodium-Glucose Transporter 2 InhibitorsIBA 09/2018 - 07/2015
3	Glucagon-Like Peptide 1 (GLP 1)IBA 02/2016 - 12/2011
3	Insulin Glargine (Lantus)FDA Link 08/2015 - 03/2005
2	Sitagliptin Phosphate (Januvia)FDA Link 12/2020 - 01/2013
2	Liraglutide FDA Link 02/2017 - 12/2011
2	Dipeptidyl-Peptidase IV InhibitorsIBA 02/2016 - 01/2013
2	Metformin (Glucophage)FDA LinkGeneric 02/2016 - 07/2011
2	InsulinsIBA 01/2016 - 01/2007
2	SuspensionsIBA 05/2015 - 07/2013
2	C-PeptideIBA 10/2014 - 01/2013
2	Short-Acting InsulinIBA 01/2007 - 01/2002
1	semaglutideIBA 12/2020
1	Interleukin-7 (Interleukin 7)IBA 12/2019
1	monoclonal antibody RN168IBA 12/2019
1	Sodium-Glucose Transporter 1IBA 09/2018
1	Glucagon-Like Peptide-1 ReceptorIBA 02/2017
1	IDegLiraIBA 02/2017
1	DiamondIBA 01/2017
1	empagliflozinIBA 02/2016
1	Monoclonal AntibodiesIBA 10/2014
1	otelixizumabIBA 10/2014
1	Glucagon (Glukagon)FDA Link 01/2013
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2013
1	insulin glulisine FDA Link 06/2011
1	gamma-glutamylaspartic acidIBA 06/2011
1	IncretinsIBA 09/2009

Therapy/Procedure

29	Therapeutics 01/2021 - 01/2002
21	Glycemic Control 01/2022 - 01/2002
9	Injections 01/2022 - 01/2002
1	Intramuscular Injections 01/2016
1	Protective Devices (Safety Device) 01/2016
1	Drug Tapering 07/2015
1	Catheters 06/2011
1	Critical Care (Surgical Intensive Care) 03/2004